Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid.
Sauer
M
M
Department of Pediatrics, University of Jena, Germany.
Gruhn
B
B
Fuchs
D
D
Altermann
W W
WW
Greinacher
A
A
Völpel
H
H
Zintl
F
F
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000276:immunology*; D016026:Bone Marrow Transplantation; D002809:Chondroitin Sulfates / Q000276:immunology*; D003871:Dermatan Sulfate / Q000276:immunology*; D004338:Drug Combinations; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects; D006496:Heparinoids / Q000276:immunology*; D006497:Heparan Sulfate / Q000276:immunology*; D024764:Hirudin Therapy; D006801:Humans; D011486:Protein C / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; D011486:Protein C; D011994:Recombinant Proteins; C035838:danaparoid